Thomson Reuters/Verus Upgrades CytRx to “Buy” (CYTR)
CytRx (NASDAQ:CYTR) was upgraded by equities researchers at Thomson Reuters/Verus from a “hold” rating to a “buy” rating in a research report issued on Monday, AnalystRatingsNetwork.com reports.
CytRx (NASDAQ:CYTR) traded up 0.87% on Monday, hitting $2.31. The stock had a trading volume of 352,329 shares. CytRx has a 1-year low of $1.59 and a 1-year high of $3.65. The stock has a 50-day moving average of $2.61 and a 200-day moving average of $2.48. The company’s market cap is $70.4 million.
CytRx (NASDAQ:CYTR) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.08. On average, analysts predict that CytRx will post $-0.73 earnings per share for the current fiscal year.
Separately, analysts at Aegis reiterated a “buy” rating on shares of CytRx in a research note to investors on Monday, September 30th. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $5.27.
CytRx Corporation as (NASDAQ:CYTR) is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, specializing in oncology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.